Elios Therapeutics LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2014-01-01
- Employees
- -
- Market Cap
- -
Autologous TLPO Vaccine Basket
Phase 2
Active, not recruiting
- Conditions
- Tumor, SolidTumor MetastasisCancerTumor
- Interventions
- Biological: Tumor lysate, particle only (TLPO) vaccine
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Elios Therapeutics, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06175221
- Locations
- 🇺🇸
Southside Medical Center, Greenville, South Carolina, United States
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Phase 1
Completed
- Conditions
- Metastatic Melanoma
- Interventions
- Drug: TLPLDC Vaccine
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Elios Therapeutics, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02678741
- Locations
- 🇺🇸
John Wayne Cancer Institute/Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Phase IIB TL + YCWP + DC in Melanoma
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Elios Therapeutics, LLC
- Target Recruit Count
- 187
- Registration Number
- NCT02301611
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Northside Hospital Cancer Institute, Atlanta, Georgia, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States